CAS NO: | 1189452-53-6 |
包装: | 1mg |
市场价: | 3704元 |
Cas No. | 1189452-53-6 |
别名 | 苯扎贝特-D4,BM15075-d4 |
Canonical SMILES | ClC1=C([2H])C([2H])=C(C(NCCC2=CC=C(OC(C)(C)C(O)=O)C=C2)=O)C([2H])=C1[2H] |
分子式 | C19H16ClD4NO4 |
分子量 | 365.8 |
溶解度 | DMSO: slightly soluble |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Bezafibrate-d4 is intended for use as an internal standard for the quantification of bezafibrate by GC- or LC-MS. Bezafibrate is a non-selective agonist of peroxisome proliferator-activated receptors (PPARs; EC50s = 50, 60, and 20 μM for human PPARα, PPARγ, and PPARδ, respectively).1 It reduces triglyceride levels and the size of lipid droplets in an oleic acid-induced HepaRG hepatocyte model of steatosis when used at a concentration of 25 μM.2 Bezafibrate (10 mg/kg per day) reduces plasma VLDL and LDL mass and triglyceride and free fatty acid levels in a high-fructose plus lard diet-induced rat model of insulin resistance.3 |1. Willson, T.M., Brown, P.J., Sternbach, D.D., et al. The PPARs: From orphan receptors to drug discovery. J. Med. Chem. 43(4), 527-550 (2000).|2. Rogue, A., AnthÉrieu, S., Vluggens, A., et al. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. Toxicol. Appl. Pharmacol. 276(1), 73-81 (2014).|3. Matsui, H., Okumura, K., Kawakami, K., et al. Improved insulin sensitivity by bezafibrate in rats: Relationship to fatty acid composition of skeletal-muscle triglycerides. Diabetes 46(3), 348-353 (1997). |